Aktis Oncology (NASDAQ:AKTS) Announces Quarterly Earnings Results

by · The Cerbat Gem

Aktis Oncology (NASDAQ:AKTS – Get Free Report) announced its earnings results on Thursday. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01), reports. The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $24.93 on Friday. The company’s 50 day simple moving average is $24.99 and its 200-day simple moving average is $21.15. The company has a market capitalization of $1.33 billion and a price-to-earnings ratio of -65.61. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19.

Analysts Set New Price Targets

AKTS has been the topic of a number of analyst reports. William Blair started coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating on the stock. Raymond James Financial initiated coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. JPMorgan Chase & Co. lifted their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.60.

Get Our Latest Stock Analysis on Aktis Oncology

Insider Buying and Selling at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of Aktis Oncology stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the sale, the director owned 3,506 shares in the company, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.30% of the company’s stock.

About Aktis Oncology

(Get Free Report)

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

Featured Stories